Thus, a 6-month treatment with fluoxetine (20 mg/day) attenuated the secretion of IL-17 by stimulated CD4+ and CD8+ T-cells in relapsing–remitting MS patients with depression (27). Here, CD4 is linked to myeloid sarcoma.